Healthcare provider profile · identity verified

Stephen Saylor, MD

Family Practice · KENNESAW, GA · NPI 1952330565

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	561	170
Metformin Hcl Er	Metformin Hcl	309	97
Losartan Potassium	Losartan Potassium	308	97
Amlodipine Besylate	Amlodipine Besylate	306	102
Trazodone Hcl	Trazodone Hcl	272	84
Lisinopril	Lisinopril	245	79
Pantoprazole Sodium	Pantoprazole Sodium	218	61
Levothyroxine Sodium	Levothyroxine Sodium	210	57
Tamsulosin Hcl	Tamsulosin Hcl	185	65
Gabapentin	Gabapentin	159	53
Rosuvastatin Calcium	Rosuvastatin Calcium	145	52
Oxycodone Hcl	Oxycodone Hcl	137	20
Tramadol Hcl	Tramadol Hcl	133	34
Omeprazole	Omeprazole	132	37
Glipizide	Glipizide	119	40
Simvastatin	Simvastatin	116	33
Escitalopram Oxalate	Escitalopram Oxalate	114	37
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	105	33
Pradaxa	Dabigatran Etexilate Mesylate	99	33
Montelukast Sodium	Montelukast Sodium	96	31
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	94	20
Meloxicam	Meloxicam	90	33
Jardiance	Empagliflozin	89	25
Pravastatin Sodium	Pravastatin Sodium	87	28
Zolpidem Tartrate	Zolpidem Tartrate	83	15
Metoprolol Succinate	Metoprolol Succinate	82	26
Albuterol Sulfate Hfa	Albuterol Sulfate	80	27
Allopurinol	Allopurinol	76	21
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	76	24
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	71	26
Alprazolam	Alprazolam	69	29
Carvedilol	Carvedilol	66	19
Metformin Hcl	Metformin Hcl	66	20
Alendronate Sodium	Alendronate Sodium	61	21
Atenolol	Atenolol	59	21
Metoprolol Tartrate	Metoprolol Tartrate	58	19
Finasteride	Finasteride	56	17
Furosemide	Furosemide	54	25
Humulin N	Insulin Nph Human Isophane	54	15
Ozempic	Semaglutide	54	suppressed
Clopidogrel	Clopidogrel Bisulfate	50	15
Mirtazapine	Mirtazapine	50	21
Ondansetron Odt	Ondansetron	50	11
Bupropion Xl	Bupropion Hcl	48	17
Potassium Chloride	Potassium Chloride	47	16
Methylprednisolone	Methylprednisolone	46	40
Duloxetine Hcl	Duloxetine Hcl	45	15
Arexvy	Rsvpref3 Antigen/As01e/Pf	41	41
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	41	12
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	40	13
Ibuprofen	Ibuprofen	38	16
Clonazepam	Clonazepam	37	suppressed
Methocarbamol	Methocarbamol	36	12
Testosterone	Testosterone	36	suppressed
Ezetimibe	Ezetimibe	34	11
Hydroxyzine Hcl	Hydroxyzine Hcl	34	suppressed
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	32	suppressed
Warfarin Sodium	Warfarin Sodium	32	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	31	11
Spironolactone	Spironolactone	30	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	30	suppressed
Acyclovir	Acyclovir	29	11
Morphine Sulfate Er	Morphine Sulfate	29	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	28	13
Prednisone	Prednisone	28	22
Naproxen	Naproxen	27	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	26	24
Pioglitazone Hcl	Pioglitazone Hcl	26	suppressed
Sertraline Hcl	Sertraline Hcl	26	13
Tizanidine Hcl	Tizanidine Hcl	26	suppressed
Ondansetron Hcl	Ondansetron Hcl	25	suppressed
Ipratropium Bromide	Ipratropium Bromide	24	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	23	suppressed
Hydralazine Hcl	Hydralazine Hcl	23	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	22	suppressed
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	22	suppressed
Diclofenac Sodium	Diclofenac Sodium	22	suppressed
Terazosin Hcl	Terazosin Hcl	22	suppressed
Pregabalin	Pregabalin	21	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	21	suppressed
Baclofen	Baclofen	20	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	20	suppressed
Topiramate	Topiramate	20	suppressed
Amoxicillin	Amoxicillin	19	11
Temazepam	Temazepam	19	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	18	18
Estradiol	Estradiol	18	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	18	suppressed
Alvesco	Ciclesonide	17	suppressed
Humulin R	Insulin Regular, Human	17	suppressed
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	17	suppressed
Hydromorphone Hcl	Hydromorphone Hcl	16	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	15	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	15	suppressed
Lorazepam	Lorazepam	15	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	15	suppressed
Trospium Chloride	Trospium Chloride	15	suppressed
Lovastatin	Lovastatin	14	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	14	14
Veo Insulin Syringe	Syring-Needl,disp,insul,0.3 Ml	14	suppressed
Humulin 70-30	Insulin Nph Hum/Reg Insulin Hm	13	suppressed
Methadone Hcl	Methadone Hcl	13	suppressed
Nitroglycerin	Nitroglycerin	13	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	13	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	13	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	13	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	12	12
Buspirone Hcl	Buspirone Hcl	12	suppressed
Citalopram Hbr	Citalopram Hydrobromide	12	suppressed
Nystatin	Nystatin	12	suppressed
Propranolol Hcl	Propranolol Hcl	12	suppressed
Clobetasol Propionate	Clobetasol Propionate	11	suppressed
Desonide	Desonide	11	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	11	suppressed
Verapamil Er	Verapamil Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error